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Background: Regardless of infection route, the intestine is the primary site for HIV-1 infection establishment and
results in significant mucosal CD4+ T lymphocyte depletion, induces an inflammatory state that propagates viral
dissemination, facilitates microbial translocation, and fosters establishment of one of the largest HIV reservoirs. Here
we test the prediction that HIV infection modifies the composition and function of the mucosal commensal
microbiota.
Results: Rectal mucosal microbiota were collected from human subjects using a sponge-based sampling
methodology. Samples were collected from 20 HIV-positive men not receiving combination anti-retroviral therapy
(cART), 20 HIV-positive men on cART and 20 healthy, HIV-negative men. Microbial composition of samples was
analyzed using barcoded 16S Illumina deep sequencing (85,900 reads per sample after processing). Microbial
metagenomic information for the samples was imputed using the bioinformatic tools PICRUST and HUMAnN.
Microbial composition and imputed function in HIV-positive individuals not receiving cART was significantly
different from HIV-negative individuals. Genera including Roseburia, Coprococcus, Ruminococcus, Eubacterium,
Alistipes and Lachnospira were depleted in HIV-infected subjects not receiving cART, while Fusobacteria,
Anaerococcus, Peptostreptococcus and Porphyromonas were significantly enriched. HIV-positive subjects receiving
cART exhibited similar depletion and enrichment for these genera, but were of intermediate magnitude and did
not achieve statistical significance. Imputed metagenomic functions, including amino acid metabolism, vitamin
biosynthesis, and siderophore biosynthesis differed significantly between healthy controls and HIV-infected subjects
not receiving cART.
Conclusions: HIV infection was associated with rectal mucosal changes in microbiota composition and imputed
function that cART failed to completely reverse. HIV infection was associated with depletion of some commensal
species and enrichment of a few opportunistic pathogens. Many imputed metagenomic functions differed between
samples from HIV-negative and HIV-positive subjects not receiving cART, possibly reflecting mucosal metabolic
changes associated with HIV infection. Such functional pathways may represent novel interventional targets for HIV
therapy if normalizing the microbial composition or functional activity of the microbiota proves therapeutically
useful.
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HIV-1 transmission and replication occur primarily at
mucosal sites. There is increasing recognition that
HIV-1 infection is substantially a mucosal disease with
systemic manifestations [1]. Regardless of infection route,
gut-associated lymphoid tissue (GALT) is the major
site of virus replication early in HIV infection due to
local retention, enhanced activation states and increased
memory immune function of GALT CD4+ T lymphocytes
as compared to peripheral blood mononuclear cells
(PBMCs) [2-4]. Accordingly, acute HIV infection results
in massive depletion of GALT CD4+ T lymphocytes with
slow and only partial reconstitution with combination
anti-retroviral therapy (cART) [1,5-8]. Other reports have
indicated complete intestinal reconstitution of CD4+ T cells
in subjects receiving cART that have sustained undetectable
HIV replication for many years [9]. In health, lymphocyte-
mediated inflammatory processes naturally occur, in part,
as a response to ongoing luminal antigenic stimulation
[10] and help shape immune and inflammatory responses
[11,12]. However, HIV-induced immunological imbalance
results in pathological manifestations including first acute
and then chronic mucosal tissue inflammation, systemic
immunological activation, increased epithelial permeabil-
ity and systemic microbial translocation [13-16]. Indeed,
local mucosal (and distant, peripheral) inflammation has
emerged as a key process in HIV infection, dissemination,
pathogenesis and possibly perpetuation [17]. Thus, strat-
egies to reverse or reduce HIV-specific as well as more
generalized subsequent inflammation could help prevent
HIV infection sequelae and dissemination.
One potential source of such inflammation is intestinal
bacteria. Commensal microbiota have major effects on
the biologic state of the host cell types in the mucosal
compartment. They modulate epithelial processes con-
trolling stem cell replenishment, barrier permeability
and microbial intrusion [18,19], mucosal lymphocyte
development and IL-17- and IL-22- dependent immune
surveillance to microbial challenge [18,20,21], and muco-
sal myeloid (macrophage, dendritic cell, and neutrophil)
microbial surveillance and immune regulation [22-25].
Given that HIV is associated with intestinal inflammation
and that intestinal microbiota can be altered in inflamma-
tory diseases, intestinal microbial compositional aberrations
might be expected in HIV-infected individuals [26,27].
However, only minor differences in abundance of a few
specific pathogens have been observed in HIV-infected
human feces [28], and larger-scale studies of fecal micro-
biota involving simian immunodeficiency virus (SIV) indi-
cate no significant compositional differences from healthy
controls [29,30]. The discrepancy between expectations
and published observations could indicate that: 1) no
significant changes in microbial composition occur in
HIV-infected subjects, and 2) any major changes inmicrobial composition of HIV-infected subjects are minor
and/or easily masked. The latter might be possible if, for
example, mucosal, as opposed to luminal, bacteria were
differentially abundant in HIV-infected subjects.
The relative inaccessibility of the intestine for direct
sampling has historically made fecal sampling from
stool the standard for investigating such associations.
While informative, some studies indicate that human
fecal microbiota composition from stool differs from that
of the intestinal mucosa [26,31,32], suggesting potentially
different grooming mechanisms. Accordingly, methods
of collecting unperturbed mucosal bacteria are highly
desirable, as mucosal communities might interact more
intimately with the host mucosal immune system [33].
Therefore, to investigate our hypotheses that HIV in-
fection is associated with altered intestinal microbial
composition, we utilized a rectal mucosal sampling strategy
involving small, anally-inserted sponges to absorb mucosal-
derived bacteria. These samples, collected from three
human cohorts, enabled assessment of whether the in-
testinal mucosal microbiome composition or function
varied with HIV infection and allowed investigation of the
ecologic influence of cART.
Methods
Subject recruitment
The protocol was designed by the investigators and
approved by the UCLA Office of the Human Research
Protection Program Institutional Review Board (UCLA
IRBs #11-001592 and #10-000750) with all participants
providing written informed consent. Protocol-based inclu-
sion criteria required that only men age ≥18 years were
recruited into this pilot study. Subjects were divided into
three groups: 20 healthy HIV-negative control subjects; 20
healthy HIV-positive subjects on chronic cART; and 20
healthy HIV-positive subjects not on cART (cART-naïve
or not on cART for ≥3 months). Exclusion criteria included:
being female; having history of inflammatory bowel disease
(IBD); having any active inflammatory conditions affecting
the rectum; and use of rectally administered medications,
including over-the-counter enemas, within 48 hours.
Sample procurement
All subjects (as specified above) were seen once in the
UCLA Digestive Diseases Clinic for sample collection.
Following a brief history, physical examination and con-
firmation of inclusion/exclusion criteria, as well as con-
firmation of subject-reported HIV serostatus (PCR and
HIV-1 antibody test), subjects received a clinician-applied
preparatory enema (118-ml saline enema). Subjects were
asked to retain the fluid for at least 5 minutes and then
expel the fluid into a toilet. While this procedure could
conceivably disturb mucosal surface contents, it was
deemed necessary to eliminate stool that might otherwise
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rest, mucosal sampling by sponge collection took place,
using previously reported methods used for secreted anti-
bodies and cytokines [34,35]. Briefly, two ophthalmic eye
spears (Beaver Visitec, Waltham, MA, USA) were simultan-
eously inserted into the rectum via anoscope, as previously
reported [34,35], and allowed to absorb mucosal material
for 5 minutes. Samples were immediately placed on ice and
transported to the laboratory for immediate processing.
Sample preparation and 16S V4 sequencing analysis
Sponges were removed from their plastic stems and indi-
vidually placed in 0.5-ml tubes (Eppendorf, Hauppauge,
NY, USA), which had the distal end previously pierced
using a sterile 18-gauge needle (BD Biosciences, San Jose,
CA, USA); each of these individual tubes were then placed
into 2-ml tubes (Eppendorf, Hauppauge, NY, USA).
Bacteria were quickly eluted and pelleted by adding
100 μl of 25 mM HEPES, 50 mM NaCl, 1% Triton-X, 1
mM DTT, and 5 mM EDTA and centrifuging in an
Eppendorf 5415D centrifuge (Eppendorf, Hauppauge,
NY, USA) for 30 s. This collection step was repeated
with another 100 μl of the elution buffer above. Super-
natant was immediately removed and pellets were frozen
in a −80° freezer (Model: ELT1786-9-D40, Thermo Scien-
tific, Asheville, NC, USA) with a backup phone system,
until further processing.
Genomic DNA was extracted from the 60 samples using
the PowerSoil DNA Isolation Kit (MO BIO Laboratories,
Carlsbad, CA, USA), and a 30-second beat-beating step
using a Mini-Beadbeater-16 (BioSpec Products, Bartlesville,
OK, USA). High-throughput sequencing analysis of bacter-
ial rRNA genes was performed using extracted genomic
DNA as the templates. One hundred microliter amplifica-
tion reactions were performed in an MJ Research PTC-200
thermal cycler (Bio-Rad Inc., Hercules, CA, USA) and
contained: 50 mM Tris (pH 8.3), 500 μg/ml bovine
serum albumin (BSA), 2.5 mM MgCl2, 250 μM of each
deoxynucleotide triphosphate (dNTP), 400 nM of each
primer, 4 μl of DNA template, and 2.5 units JumpStart
Taq DNA polymerase (Sigma-Aldrich, St Louis, MO, USA).
The PCR primers (F515/R806) targeted a portion of the
16S rRNA gene containing the hypervariable V4 region,
with the reverse primers including a 12-bp barcode [36].
All primer sequences are available in Additional file 1.
Thermal cycling parameters were 94°C for 5 minutes; 35
cycles of 94°C for 20 seconds, 50°C for 20 seconds, and
72°C for 30 seconds, followed by 72°C for 5 minutes. PCR
products were purified using a MinElute 96 UF PCR
Purification Kit (Qiagen, Valencia, CA, USA). DNA
sequencing was performed using an Illumina HiSeq 2000
(Illumina, Inc., San Diego, CA, USA). Clusters were cre-
ated using template concentrations of 1.9 pM and PhiX at
65 K/mm2, (manufacturer’s recommendations for sampleswith uneven distributions of A, C, G and T). One hundred
base sequencing reads of the 5′ end of the amplicons and
seven base barcode reads were obtained using the sequen-
cing primers listed in Additional file 1. De-multiplexing,
quality control, and operational taxonomic unit (OTU)
binning were performed using Quantitative Insights into
Microbial Ecology (QIIME) [37].
The total initial number of sequencing reads was
71,581,480. Low quality sequences were removed using
the following parameters: Q20, minimum number of
consecutive high-quality base calls = 100 bp, maximum
number of N characters allowed = 1, maximum number of
consecutive low-quality base calls allowed before truncating
a read = 3. Numbers of sequences removed using the
aforementioned quality control parameters were: barcode
not in mapping file (35,296,547), reads too short after
quality truncation (4,926,462), and too many Ns (5,431).
Remaining reads numbered 31,353,040, which were then
used to pick OTUs from the GreenGenes reference
database (May 18, 2012 database); this database automatic-
ally bins OTUs at 97% identity, ensuring the resulting data
were compatible with phylotypic investigation of commu-
nities by reconstruction of unobserved states (PICRUSt)
analysis. Due to alignment failure, an additional 1,511,116
reads were discarded during OTU picking, providing
29,841,924 reads for downstream analysis.Bioinformatic analysis
Rarefaction and diversity analysis
After picking OTUs from the GreenGenes reference
database, rarefaction was performed to 85,900 (corre-
sponding to the sample with the fewest reads) reads per
sample using the QIIME software suite (version 1.6)
running on an Ubuntu virtual machine [37]. Alpha diver-
sity metrics used included Phylogenetic Diversity, Chao1,
observed species and Shannon index. For all sampling
depths, each plotted point represents the average of
ten random samplings. The comparison of alpha diversity
between the three groups was performed using the two-
sided Student t-test. Beta diversity analysis was performed
in QIIME and utilized unweighted UniFrac distances
to estimate sample distributions. Adonis significance
analysis was performed for each pairwise comparison
of sample groups using the Adonis function from the
vegan R package [38].Taxonomic analyses
Microbial composition at each taxonomic level was defined
using the summarize_taxa function in QIIME. Prior to all
analysis of variance (ANOVA), taxa at each taxonomic
level were thresholded such that any taxon present in
fewer than 20% of samples was discarded.
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All statistical analyses were conducted using R (http://
www.r-project.org/). HIV- and cART-associated microbial
changes were calculated using ANOVA with multiple
comparison correction using q-values (R package qvalue).
Associations between imputed metagenomic functions
and HIV infection were calculated using Kruskal-Wallis
ANOVA and corrected for multiple comparisons using
q-values. All taxonomic associations reported were sig-
nificant q <0.15 unless stated otherwise. All metagenomic
associations reported were significant at q <0.25.
Comparison of microbial composition with respect
to cART drug classes
For this analysis, subjects were assigned to one or more
groups based on the classes of prescribed cART drugs.
Genus-level taxa were then analyzed for differences be-
tween subjects from each individual group compared
with all cART(−) subjects. For each ANOVA comparison,
genera that were not present in at least 20% of cART(+)
subjects were first removed.
Metagenomic imputation
PICRUSt is a well-documented tool designed to impute
metagenomic information based on 16S input data (http://
picrust.github.io/picrust). Sample metagenomic imputation
was performed using the default settings of PICRUSt
(version 0.9.1). The resulting metagenomic data were
then entered into the HMP unified metabolic analysis net-
work (HUMAnN) pipeline (version 0.98) [39] to sort indi-
vidual genes into Kyoto encyclopedia of genes and
genomes (KEGG) pathways representing varying propor-
tions of each imputed sample metagenome. Both PICRUSt
and HUMAnN analyses were performed using the ter-
minal interface of a QIIME virtual machine running the
Ubuntu operating system.
Results
Rectal mucosa microbial sampling strategy
In place of bowel preparation, all subjects first received a
saline enema to void solid fecal contents from the rectal
vault. Two absorbent ophthalmic sponges were then
applied, under direct vision via anoscope, to opposing
sides of the rectal mucosa (Figure 1), enabling collection
of measureable levels of bacteria, protein and metabolites.
Despite their small volume, eluate from each sponge
allowed recovery of approximately 5 × 107 ± 4.4 × SD 107
of bacterial cells and approximately 105 μg ± SD 75.9 of
protein via bacterial hemocytometer and Bradford assay,
respectively. To account for possible micro-biogeographic
variations in microbial composition or abundance, material
obtained from two sponges from each subject were pooled
for further analyses. We did not attempt to determine
whether this sampling methodology artificially enriched ordepleted certain microbes, proteins, or metabolites, so we
could not eliminate the possibility.
Samples were collected from 20 healthy controls (HC),
20 healthy HIV-positives on cART (cART(+)) and 20
healthy HIV-positive subjects off cART (cART(−)) for at
least three months (Table 1). All collected subject metadata
including age, ethnicity, viral loads, serum CD4+ T cell
counts, durations of infection, and prescribed cART drug
classes are tabulated in Table 1. Importantly, to eliminate
the potential influences of gender, only men were recruited
for this pilot study. The specific cART drugs prescribed
to cART(+) subjects are tabulated in Additional file 2.
Microbial components were lysed and analyzed for V4
16S composition using barcoded Illumina-HiSeq 2000 V4
sequencing. OTUs were then picked at a similarity thresh-
old of 97% using the GreenGenes reference database, such
that 497,365 ± SD 119,950 reads were retained for each
sample. Sequenced reads were then rarified to 85,900
reads per sample, yielding a total of 3,281 OTUs.
HIV infection alters mucosal microbial diversity
To determine whether HIV infection altered microbial
diversity of the rectal mucosa, alpha and beta diversity
metrics were analyzed. Alpha diversity is a measure of
sample-level species richness, with healthy subjects typically
exhibiting more species richness (higher alpha diversity)
than those with intestinal conditions, such as IBD, or
obesity [40,41]. Beta diversity describes inter-subject
similarity of microbial composition and facilitates identifi-
cation of broad differences between samples [42].
As groups, the HC and cART(+) subjects revealed very
similar alpha diversity rarefaction profiles. However,
cART(−) subjects exhibited significant reduction of alpha
diversity using the Chao1 diversity metric, which accur-
ately estimates OTU richness for microbial communities
[43], compared with HC, indicating HIV infection is
associated with a potential collapse in alpha diversity (two
tailed t-test, P ≤0.05 at all sampling depths >17,188)
(Figure 2A). A similar, though insignificant trend was
observed between cART(+) and cART(−) subjects (two
tailed t-test, P = 0.05, 0.1 for all sampling depths >10).
Similar overall trends were observed using two other
alpha diversity metrics, including observed species and
Phylogenetic Diversity, though neither metric yielded
significant differences between any of the three cohorts,
suggesting any difference in alpha diversity was minor
(Additional file 3). Together, these derivative data suggest
HIV infection resulted in a slight reduction of alpha
diversity in cART(−) subjects that was reversed to near
equivalence with HC in cART(+) subjects. Beta diversity
analysis was then performed using the unweighted
unifrac distance metric to determine whether HC, cART(+)
or cART(−) subjects differed in their microbial compos-
ition. Adonis analysis of the resulting unifrac distance
Table 1 Human subject metadata
cART(−) cART(+) HC
n 20 20 20 Subject metadata
Gender All male All male All male
Age, years 40.9 (± 11.4) 46.3 (± 9.2) 48.6 (±12)
Viral Loads 158,147 (± 366,197) 3,563 (± 14,333) N/A
Years infected 8.9 (± 8.8) 14.2 (± 6.5) N/A
Serum CD4 levels 439.6 (± 271.8) 534 (± 246) NT
Hispanic 4 1 5 Ethnicity
Black 13 14 9
Caucasian 3 5 5
Other 0 0 1
NNRTI N/A 9 N/A cART drugs prescribed
NRTI N/A 18 N/A
PI N/A 12 N/A
II (raltegravir) - 4 -
Results are presented as number or mean (± SD). (cART(−), healthy HIV-positive men off combination anti-retroviral therapy (cART) for at least three months;
cART(+), healthy HIV-positive men on (cART); HC, healthy controls; NT, not tested; N/A, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; PI; protease inhibitor; II, integrase inhibitor.
Figure 1 Schematic of sampling and bioinformatic methodology. Rectal mucosa secretions were collected from 60 human subjects as
shown and subjected to high-throughput deep V4 16S sequencing. Alpha and beta diversity analyses were then performed, which suggested
microbial composition was altered in HIV-infected subjects who were not receiving combination anti-retroviral therapy (cART). Microbial
differences in these subjects were identified and compared with HIV-infected subjects receiving cART. In addition, the different classes of cART
were analyzed to determine whether any class was significantly associated with differences in microbial composition. Imputed metagenomic
differences between HIV-infected subjects not receiving cART and healthy control subjects were then identified and compared between the
three patient cohorts. PICRUSt, phylotypic investigation of communities by reconstruction of unobserved states; HUMAnN, HMP unified metabolic
analysis network.
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Figure 2 Alpha and beta diversity. (A) Chao1 alpha diversity indicated subjects on combination anti-retroviral therapy (cART(−)) had reduced
species richness than healthy controls (HC) and subjects on (cART(+)), though only the comparison with HC was significant (t-test, P ≤0.05 at all
sampling depths >17,188). Abundance curves for HC and cART(+) subjects were nearly indistinguishable. (B) Beta diversity was analyzed by
unweighted unifrac analysis using the first and fourth principal components. These principal components were selected because principal
coordinate 1 (PC1) was significantly different between cART(−) and cART(+) subjects (Kruskal-Wallis, P = 0.02) and both PC1 and PC4 were
significantly different between cART(−) and HC subjects (Kruskal-Wallis, both P <0.05). HC subjects (blue) clustered relatively tightly with cART(+)
subjects (yellow), whereas cART(−) subjects (red) were more diffusely scattered along PC1 and PC4 (Adonis, for cART(+) vs cART(−) P = 0.06, and
for cART(−) versus HC P = 0.02). (C) Phylum level composition of each subject was sorted based on HIV and cART status. The abundance of
Firmicutes was significantly reduced in cART(−) subjects compared with healthy subjects (analysis of variance (ANOVA), q = 0.06) while
Fusobacteria were significantly enriched (ANOVA, q = 0.11).
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cART(−) subjects were significantly different from HC
subjects (P = 0.017); 2) cART(+) and cART(−) subjects
overlapped but had slightly different trends (P = 0.053);
and 3) cART(+) subjects were not statistically different
from HC subjects (P = 0.1). Principal coordinate analysis
(PCoA) of the first and fourth principal components of the
unweighted unifrac distance matrix allowed visualization of
these differences (Figure 2B). The variation captured in the
first, third and fourth principal components (14%, approxi-
mately 5%, and 4% of total variation, respectively) of the
unweighted unifrac analysis varied significantly between
cART(−) and HC subjects (Kruskal-Wallis, all P ≤0.05).
Excluding age (Pearson correlation with principle coordin-
ate 1 (PC1), P <0.001), which is known to correlate with
changes in intestinal microbiota composition [26,44,45], no
other subject-reported metadata (including serum CD4
levels, serum viral titers, duration of infection, and ethni-
city) significantly correlated with any of the first five prin-
cipal components of the combined data. Thus, both alpha
and beta diversity analysis suggested that HIV infection
resulted in ecological changes relative to healthy controls
that were partially normalized in cART(+) subjects.As an initial confirmation of the beta diversity predicted
differences, the microbial composition of samples from
HIV-infected (both cART(+) and cART(−)) subjects was
compared with that of HC subjects at the phylum level.
Significant phylum level differences were corrected for
multiple comparisons using a significance cutoff of q <0.15
[46]. Samples obtained from cART(−) subjects were enriched
with Fusobacteria (ANOVA, q = 0.1) and depleted of
Firmicutes (ANOVA, q = 0.058), compared to HC samples
(Figure 2C). However, cART(+) subjects displayed only
intermediate enrichment of Fusobacteria (ANOVA, q =
0.27) and depletion of Firmicutes (ANOVA, q = 0.27).
Therefore, this analysis also suggested microbial compos-
ition in cART(−) subjects was significantly different from
HC and that the composition of cART(+) was partially,
though incompletely, normalized to that of HC.
Numerous mucosal microbial taxa are differentially
abundant in cART(−) subjects
To identify all bacterial taxa that were differentially abun-
dant in cART(−) subjects, OTUs were binned at every
taxonomic level, thresholded such that any taxon present
in fewer than 20% of samples was discarded, and analyzed
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HC subjects. The identified microbial enrichments and
depletions are shown according to their taxonomic as-
signment in Figure 3. Numerous Clostridiales genera
were depleted in cART(−) subjects, including Lachnospira,
Coprococcus, Eubacterium, Roseburia, and Ruminococcus.
Furthermore, the depletion of the Alistipes genus from the
Bacteroidetes phylum and an unclassified genus from the
Veillonellaceae family was also seen. Conversely, two
Clostridiales genera, Peptostreptococcus and Anaeroco-
ccus, one Bacteroidiales genus, Porphyromonas, and one
Fusobacteriales genus, Fusobacterium, were enriched in
cART(−) subjects compared with HCs. All enriched and
depleted bacteria were significant at q <0.15 except the
enrichment of Porphyromonas, which was significant at
q = 0.157. Combined, these findings suggest that HIV in-
fection, in the absence of cART, results in extensive micro-
bial compositional alterations at the rectal mucosal surface.
CART partially restores mucosal microbiota composition
Given the systemic morbidity, mortality, and microbial
changes associated with untreated HIV-1 infection, the
influence of cART on microbial composition was of inter-
est. This would ideally be tested longitudinally on subjects
as they transitioned onto cART. However, given the diffi-
culty in recruiting and retaining compliant patients, differ-
ences were compared between cART(+) and cART(−)
subjects. First, the abundances of genera that were altered
in cART(+) subjects were analyzed with respect to HC
subjects. The genera Roseburia and Coprococcus appeared
significant according to the uncorrected P-value (ANOVA,
P <0.05), but no genera were significantly different in
cART(+) subjects compared with HC subjects at q <0.15




















Figure 3 Phylogenetic differences in subjects not on combination ant
taxa that were significantly associated with HIV infection. Blue boxes indica
indicate clades or taxa that were enriched in cART(−) subjects; and grey bo
HIV, and are only included to contextualize taxa that were differentially abu
were significant at q <0.15 except Porphyromonas (q = 0.155).of the genera that significantly differed in cART(−) subjects
were of intermediate significance in cART(+) subjects
(data not shown). To allow qualitative comparison of the
extent to which cART normalized the rectal microbiota in
cART(+) subjects relative to cART(−) and HC subjects,
bean plots of each relevant genus were generated for each
subject group (Figure 4). Every genus that was enriched
or depleted in cART(−) subjects was similarly, but less
drastically, enriched or depleted in cART(+) subjects
relative to HC subjects.
Given that long-term cART can substantially reconstitute
CD4+ T cells, duration of cART might be expected to
correlate with increased normalization of these bacteria.
Unfortunately, durations of compliant cART could not be
reliably estimated in this study. As a proxy, duration of
infection of cART(+) subjects was correlated with the
abundance of each genus above. However, none of the
genera positively correlated significantly with duration of
infection. Hence, cART appeared to partially remediate
microbial composition from that in cART(−) subjects,
but failed to completely restore the microbiota to levels
observed in HC. This interpretation should be tempered
by the proxy parameter for treatment duration and quality,
and a cohort size that limits sensitivity in detecting
temporal microbial changes.
Imputed metagenomic metabolic functions significantly
vary with HIV infection in the absence of cART
Having identified distinct microbial changes in cART(−)
subjects compared to HC subjects, concomitant func-
tional metagenomic differences might also be expected.
Metagenomic composition is traditionally defined using
shotgun sequencing. In the absence of measured meta-

















i-retroviral therapy (cART(−)). A phylogenetic tree populated with
te taxa that were significantly depleted in cART(−) subjects; Red boxes
xes indicate clades or taxa that were neither enriched nor depleted in
ndant. All associations were determined by analysis of variance and
Figure 4 Combination anti-retroviral therapy (Cart) partially normalizes microbial composition. Genera that were significantly depleted or
enriched in subjects not on cART (cART(−)) were analyzed in those on cART (cART(+)) and healthy controls (HC) to reveal the extent to which
cART use reversed microbial changes. While no genera were significantly different between cART(+) and HC subjects, cART(+) subjects displayed
intermediate levels of enrichment and depletion in all tested genera. The largest vertical black bars in each bean plot represent group averages.
Thin vertical black bars represent at least one sample. The x-axis represents the percent abundance of genera for each sample; *q <0.15 relative
to HC.
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to bioinformatically impute sample metagenomes and de-
termine relative genomic abundances of KEGG metabolic
pathways from all subjects, respectively. PICRUSt allows
imputation of most microbial genomes present in each
sample based on sequence similarity of input
GreenGenes sequences to sequenced reference genomes.
When combined with HUMAnN, a separate bioinformatic
tool that organizes metagenomic data into relative abun-
dances of KEGG pathways per sample, the resulting data
are highly comparable to sequenced metagenomic data
and observed metabolomic data [26,47].
Using these bioinformatic tools, metagenomic functions
were compared between cART(−), cART(+) and HC
subjects. For these metagenomic analyses, the q-value
threshold for correcting multiple comparisons was relaxed
to include q <0.25 comparisons in agreement with previous
studies using this methodology [26]. Like the analyses
above, no significant differences were observed between
cART(+) and HC subjects or between cART(+) and
cART(−) subjects after correction for multiple compari-
sons. However, 10 KEGG pathways were significantly dif-
ferent between cART(−) and HC subjects (Kruskal-Wallis,
q <0.25). Plotting these pathways with respect to cART
status revealed that the distribution of these pathways was
similar to the distribution of enriched and depleted genera
(Figure 5); While cART(−) subjects exhibited the most
enrichment or depletion of each pathway, cART(+) subjects
had intermediate levels of metagenomic pathwayabundance relative to HC (Figure 5). Overall, the
metagenomes of cART(−) subjects tended to be depleted
of amino acid production, amino acid metabolism, CoA
biosynthesis, and fructose/mannose metabolism com-
pared with HC subjects. Instead, the microbiota of cART
(−) subjects were metagenomically enriched for glutathi-
one metabolism, selenocompound metabolism, folate
biosynthesis and siderophore biosynthetic genes. These
results indicate that HIV infection in the absence of cART
results in significant functional metagenomic differences
that are not fully restored with cART. Such functional
differences may reflect the functions that HIV-infected
mucosa select for and could have downstream implica-
tions on vitamin and nutrient availability for the host.Discussion
This study represents one of the first attempts to define
changes in the mucosal microbiota composition in HIV in-
fection and revealed several HIV-dependent changes in the
mucosal microbiota. HIV infection in the absence of cART
was associated with significant increases in Fusobacterium,
Anaerococcus, Peptostreptococcus and Porpyromonas spe-
cies and significant decreases in Roseburia, Alistipes,
Coprococcus, Eubacterium, Ruminococcus and Lachnospira
species. Surprisingly, of the genera enriched in cART(−)
subjects all are (i) commonly isolated from the oral cav-
ity and (ii) considered opportunistic pathogens. Indeed,
Anaerococcus, Porphyromonas and Peptostreptococcus
Selenocompound metabolism
Glutathione metabolism
Fructose and mannose metabolism
Ala, Asp and Glu metabolism
Val, Leu and Ile biosynthesis
Lys biosynthesis
Phe, Tyr and Trp biosynthesis
Pantothenate and CoA biosynthesis














Figure 5 Imputed metagenomic differences between subjects not on combination anti-retroviral therapy (cART(−)) and healthy control
(HC) subjects. The relative abundance of metabolic pathways encoded in each imputed sample metagenome was analyzed by HIV infection
status of each subject using box plots. From these box plots, clear differences are observed between the relative abundance of several imputed
metagenomic functions between cART(−) subjects and HC. Significance of each comparison was determined using Kruskal-Wallis one way
analysis of variance. Box plots of subjects on cART (cART (+)) are included to provide context for each comparison. Vertical black bars represent
group averages. The x-axis represents the percent abundance of pathways for each imputed sample metagenome. Whiskers represent the
interquartile ranges multiplied by 1.5; *q <0.25 relative to HC.
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ised individuals [48,49].
Fusobacterium species commonly colonize the oral cav-
ity and are classified as pathogenic due to: 1) their ability
to integrate into healthy oral streptococcal biofilms and
subsequently facilitate colonization of other periodontal
pathogens [50] and 2) their ability to translocate into the
blood and contribute to bacteremia, preterm birth, organ
abscesses and possibly coronary artery disease [51-54].
The levels of intestinal enrichment of Fusobacterium
observed in cART(−) subjects is rare and typically only
occurs in the context of severe disease, like colorectal
adenoma and appendicitis [55-58]. Indeed, HIV-infected
subjects are three times more likely than uninfected indi-
viduals to develop acute appendicitis, and have an increased
risk of colorectal cancer despite advances in cART [59-61].
It is therefore possible that the increased mucosal con-
centration of Fusobacterium may contribute to observed
increases in some co-morbidities in HIV-infected pa-
tients. Conversely, genera depleted in cART(−) subjects,
including Roseburia, Alistipes, Coprococcus, Eubacterium,
Ruminococcus and Lachnospira tend to be non-pathogenic.
In IBD, Roseburia species are also commonly depleted,
which is thought to be detrimental to the host due to their
tendency to produce anti-inflammatory short-chain fatty
acids (SCFAs) from fiber sources [26,62,63]. In the course
of publication of the present study, there has been anindependent report of the impact of HIV infection on in-
testinal mucosal microbial composition and metabolic
function [64]. The findings in both studies were largely
concordant, and in particular highlighted the impact of
HIV infection on amino acid metabolism (most notably
tryptophan catabolism), and its relevance as a modifier
of mucosal immune homeostasis
This study also revealed several important, imputed
metagenomic functional pathways that varied in abundance
between cART(−) and HC subjects. Although previous
studies have suggested that intra-subject metagenomic
content tends to remain relatively stable over time inde-
pendent of microbial composition, new studies suggest
metagenomic content can vary in the context of certain
diseases [26,41,44]. These results, combined with the ob-
served microbial compositional changes, suggest differing
metabolic functions arise based on the different microbial
communities more pronounced in HIV-infected subjects.
Genes encoding amino acid biosynthesis and metabolism,
CoA biosynthesis, selenocompound metabolism, glutathi-
one metabolism and folate biosynthesis were composition-
ally altered in cART(−) subjects. This imbalance might
indicate that free vitamins and nutrients available to HIV-
infected hosts might be altered. Interestingly, siderophore
biosynthetic genes were enriched in cART(−) subjects.
Siderophores act as quorum sensing molecules for gram-
negative organisms, so the enrichment of this pathway
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communication in cART(−) subjects. cART(−) subjects
encoded fewer genes for fructose and mannose metabol-
ism, which may be reflective of altered environmental
nutrient availability or the differing metabolic potential
of bacterial species that best adapt to such environments.
Besides illuminating the metabolic potential of the under-
lying bacterial community, these pathways might be
exploitable to help normalize microbial composition of
HIV-infected subjects if microbial remediation strategies
prove warranted. Given the role of diet in driving mi-
crobial composition, one could imagine exploiting such
differences in metabolic function by dietary optimization
to enrich for preferred bacteria [65-67].
Conclusions
Significant functional and compositional differences in
rectal microbiota were observed between cART(−) and
HC subjects; these were incompletely normalized by
cART in cART(+) subjects. However, an HIV-associated
reduction in alpha diversity was adequately normalized by
cART. Phylogenetic profiles of cART(−) subjects reflected
enrichment for opportunistic pathogens and depletion of
nonpathogenic genera. The differing imputed metagenomic
compositions between cART(−) subjects and HC subjects
suggested HIV infection altered the rectal ecosystem and
selected for different microbial metagenomic functions.
Additional files
Additional file 1: Primers used for the V4 rRNA PCR and
sequencing analysis. Contains three tables containing: (1) Reverse PCR
primers used in the Illumina-based high-throughput sequence analysis
of bacterial 16S rRNA genes; (2) Forward PCR primer used in the
Illumina-based high-throughput sequence analysis of bacterial 16S
rRNA genes; and (3) Sequencing primers used in the Illumina-based
high-throughput sequence analysis of bacterial 16S rRNA genes. PCR,
polymerase chain reaction.
Additional file 2: Individual anti-retroviral drugs taken by subjects
on combination anti-retroviral therapy (cART(+)). Each cART(+)
received an average of 3.65 specific drugs that are tabulated here.
Additional file 3: Additional metrics of alpha diversity. Observed
species (A) and Phylogenetic Diversity (B) are independent metrics of
alpha diversity. Both indicated that subjects not on combination
anti-retroviral therapy (cART(−)) exhibited reduced alpha diversity relative
to both healthy controls (HC) and those on cART (cART(+)), though these
differences were not statistically significant using either metric. In both
cases, the alpha diversity curves of HC subjects and cART(+) subjects
were nearly indistinguishable.
Abbreviations
ANOVA: Analysis of variance; cART: Combination anti-retroviral therapy;
cART(+): HIV-positive subjects receiving combination anti-retroviral therapy;
cART(−): HIV-positive subjects not receiving combination anti-retroviral
therapy; HC: Healthy control; HUMAnN: HMP unified metabolic analysis
network; IBD: Inflammatory bowel disease; IL: Interleukin; KEGG: Kyoto
encyclopedia of genes and genomes; NRTI: Nucleotide and nucleoside
reverse transcriptase inhibitor; NNRTI: Non-nucleoside reverse transcriptase
inhibitor; OTU: Operational taxonomic unit; PBMC: Peripheral blood
mononuclear cell; PC: Principal component; PCoA: Principal coordinateanalysis; PCR: Polymerase chain reaction; PI: Protease inhibitor;
PICRUSt: Phylotypic investigation of communities by reconstruction of
unobserved states; QIIME: Quantitative Insights into Microbial Ecology;
SCFA: Short chain fatty acid.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JBr, PA and IM designed the study format. PA coordinated the sample
collection. IM and XL pre-processed samples and coordinated sample
storage. IM, JBr, and MT designed the analytic strategies. PR and JBo
generated sequencing data. IM, MT, JBo, PR, JJ and JBr analyzed data. IM
performed computational analysis. All authors interpreted data. IM, JBr and
PA drafted the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
The study was funded by a pilot and feasibility grant of the CURE Digestive
Disease Research Center (P30 DK041301). Additional support was provided
by the University of California, Los Angeles Center for AIDS Research (CFAR)
(5P30 AI28697) and UCLA Clinical and Translational Science Institute (UL1
TR000124). The authors would also like to acknowledge Terry Saunders,
Charina McDonald, Kathleen James, Julie Elliot, Elena Khanukhova and Justin
Akin for their hard work in recruiting and collecting specimens for this
project. Sequence data generated from this study were deposited into the
Sequence Read Archive and are available under the accession number:
SRA101259.
Author details
1Pathology and Laboratory Medicine, UCLA, 10833 Le Conte Ave 13-188 CHS,
Los Angeles, CA 90095, USA. 2Inflammatory Bowel Disease & Immunobiology
Research Institute, Cedars Sinai Medical Center, Los Angeles 90048, USA.
3Pharmacology, UCLA, Los Angeles, CA, USA. 4Plant Pathology, UC Riverside,
Riverside, CA, USA. 5Department of Medicine, UCLA, Los Angeles, CA, USA.
6Center for HIV Prevention Research, UCLA AIDS Institute, Los Angeles, CA,
USA.
Received: 17 April 2013 Accepted: 3 October 2013
Published: 12 October 2013
References
1. Veazey RS, Lackner AA: HIV swiftly guts the immune system. Nat Med
2005, 11:469–470.
2. Ullrich R, Schieferdecker HL, Ziegler K, Riecken EO, Zeitz M: Gamma delta T
cells in the human intestine express surface markers of activation and
are preferentially located in the epithelium. Cell Immunol 1990,
128:619–627.
3. Nabel G, Baltimore D: An inducible transcription factor activates
expression of human immunodeficiency virus in T cells. Nature 1987,
326:711–713.
4. Schieferdecker HL, Ullrich R, Hirseland H, Zeitz M: T cell differentiation
antigens on lymphocytes in the human intestinal lamina propria.
J Immunol 1992, 149:2816–2822.
5. Kotler DP, Reka S, Clayton F: Intestinal mucosal inflammation associated
with human immunodeficiency virus infection. Dig Dis Sci 1993,
38:1119–1127.
6. Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, Viora M, Belardelli
F, Fais S: Human intestinal lamina propria lymphocytes are naturally
permissive to HIV-1 infection. Eur J Immunol 1999, 29:1202–1208.
7. Mehandru S, Poles MA, Tenner-Racz K, Jean-Pierre P, Manuelli V, Lopez P,
Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M: Lack of mucosal
immune reconstitution during prolonged treatment of acute and early
HIV-1 infection. PLoS Med 2006, 3:e484.
8. Mehandru S, Poles MA, Tenner-Racz K, Manuelli V, Jean-Pierre P, Lopez P,
Shet A, Low A, Mohri H, Boden D, Racz P, Markowitz M: Mechanisms of
gastrointestinal CD4+ T-cell depletion during acute and early human
immunodeficiency virus type 1 infection. J Virol 2007, 81:599–612.
9. Sheth PM, Chege D, Shin LY, Huibner S, Yue FY, Loutfy M, Halpenny R,
Persad D, Kovacs C, Chun TW, Kandel G, Ostrowski M, Kaul R: Immune
McHardy et al. Microbiome 2013, 1:26 Page 11 of 12
http://www.microbiomejournal.com/content/1/1/26reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal
Immunol 2008, 1:382–388.
10. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F:
Immunoregulation in the gut: success and failures in human disease.
Gut 2002, 50(Suppl 3):III60–III64.
11. Macpherson AJ, Harris NL: Interactions between commensal intestinal
bacteria and the immune system. Nat Rev Immunol 2004, 4:478–485.
12. Abraham C, Medzhitov R: Interactions Between the Host Innate Immune
System and Microbes in Inflammatory Bowel Disease. Gastroenterology
2011, 140:1729–1737.
13. Dandekar S: Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS
Rep 2007, 4:10–15.
14. Brenchley JM, Douek DC: Microbial translocation across the GI tract. Annu
Rev Immunol 2012, 30:149–173.
15. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S,
Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B,
Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman
MM, Deeks SG, Douek DC: Microbial translocation is a cause of
systemic immune activation in chronic HIV infection. Nat Med 2006,
12:1365–1371.
16. Sandler NG, Douek DC: Microbial translocation in HIV infection: causes,
consequences and treatment opportunities. Nat Rev Microbiol 2012,
10:655–666.
17. Appay V, Sauce D: Immune activation and inflammation in HIV-1
infection: causes and consequences. J Pathol 2008, 214:231–241.
18. Brown EM, Sadarangani M, Finlay BB: The role of the immune system in
governing host-microbe interactions in the intestine. Nat Immunol 2013,
14:660–667.
19. Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West
ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL,
Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R,
Blazar BR, van den Brink MR: Interleukin-22 protects intestinal stem cells
from immune-mediated tissue damage and regulates sensitivity to graft
versus host disease. Immunity 2012, 37:339–350.
20. Belkaid Y, Naik S: Compartmentalized and systemic control of tissue
immunity by commensals. Nat Immunol 2013, 14:646–653.
21. Brestoff JR, Artis D: Commensal bacteria at the interface of host
metabolism and the immune system. Nat Immunol 2013, 14:676–684.
22. Ng SC, Kamm MA, Stagg AJ, Knight SC: Intestinal dendritic cells: their role in
bacterial recognition, lymphocyte homing, and intestinal inflammation.
Inflamm Bowel Dis 2010, 16:1787–1807.
23. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg
GF, Paley MA, Antenus M, Williams KL, Erikson J, Wherry EJ, Artis D:
Commensal bacteria calibrate the activation threshold of innate antiviral
immunity. Immunity 2012, 37:158–170.
24. Rivollier A, He J, Kole A, Valatas V, Kelsall BL: Inflammation switches the
differentiation program of Ly6Chi monocytes from antiinflammatory
macrophages to inflammatory dendritic cells in the colon. J Exp Med
2012, 209:139–155.
25. Fournier BM, Parkos CA: The role of neutrophils during intestinal
inflammation. Mucosal Immunol 2012, 5:354–366.
26. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA,
Shah SA, Leleiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ,
Huttenhower C: Dysfunction of the intestinal microbiome in
inflammatory bowel disease and treatment. Genome Biol 2012, 13:R79.
27. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D,
Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y,
Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, et al:
A metagenome-wide association study of gut microbiota in type 2
diabetes. Nature 2012, 490:55–60.
28. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, Ben Amor K,
van Schaik J, Vriesema A, Knol J, Marchetti G, Welling G, Clerici M: Early
impairment of gut function and gut flora supporting a role for alteration
of gastrointestinal mucosa in human immunodeficiency virus
pathogenesis. J Clin Microbiol 2008, 46:757–758.
29. McKenna P, Hoffmann C, Minkah N, Aye PP, Lackner A, Liu Z, Lozupone CA,
Hamady M, Knight R, Bushman FD: The macaque gut microbiome in health,
lentiviral infection, and chronic enterocolitis. PLoS Pathog 2008, 4:e20.
30. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P,
Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR,
Schmitz JE, Mansfield K, Brenchley JM, Veazey RS, Stappenbeck TS, Wang D,Barouch DH, Virgin HW: Pathogenic simian immunodeficiency virus infection
is associated with expansion of the enteric virome. Cell 2012, 151:253–266.
31. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R: Bacterial
community variation in human body habitats across space and time.
Science 2009, 326:1694–1697.
32. Stearns JC, Lynch MD, Senadheera DB, Tenenbaum HC, Goldberg MB,
Cvitkovitch DG, Croitoru K, Moreno-Hagelsieb G, Neufeld JD: Bacterial
biogeography of the human digestive tract. Sci Rep 2011, 1:170.
33. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, Ley R, Wakeland
EK, Hooper LV: The antibacterial lectin RegIIIgamma promotes the spatial
segregation of microbiota and host in the intestine. Science 2011, 334:255–258.
34. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-
Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju
C, Carballo-Diéguez A, Mauck C, McGowan I: RMP-02/MTN-006: A phase 1
rectal safety, acceptability, pharmacokinetic, and pharmacodynamic
study of tenofovir 1% gel compared with oral tenofovir disoproxil
fumarate. AIDS Res Hum Retroviruses 2012, 28:1412–1421.
35. Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G,
Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez
A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I: First phase 1
double-blind, placebo-controlled, randomized rectal microbicide trial using
UC781 gel with a novel index of ex vivo efficacy. PLoS One 2011, 6:e23243.
36. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA,
Turnbaugh PJ, Fierer N, Knight R: Global patterns of 16S rRNA diversity at
a depth of millions of sequences per sample. Proc Natl Acad Sci USA 2011,
108(Suppl 1):4516–4522.
37. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD,
Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley
ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD,
Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J,
Yatsunenko T, Zaneveld J, Knight R: QIIME allows analysis of
high-throughput community sequencing data. Nat Methods 2010,
7:335–336.
38. Oksanen J, Blanchet F, Kindt R, Legendre P, Minchin P, Oh R, Simpson G,
Solymos P, Stevens MH, Wagner H: vegan: Community Ecology Package.
In Book vegan: Community Ecology Package. City: R package version
2.0-4; 2012.
39. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, Rodriguez-
Mueller B, Zucker J, Thiagarajan M, Henrissat B, White O, Kelley ST, Methé B,
Schloss PD, Gevers D, Mitreva M, Huttenhower C: Metabolic reconstruction
for metagenomic data and its application to the human microbiome.
PLoS Comput Biol 2012, 8:e1002358.
40. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L,
Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of
faecal microbiota in Crohn’s disease revealed by a metagenomic
approach. Gut 2006, 55:205–211.
41. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE,
Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC,
Knight R, Gordon JI: A core gut microbiome in obese and lean twins.
Nature 2009, 457:480–484.
42. Lozupone C, Lladser ME, Knights D, Stombaugh J, Knight R: UniFrac: an
effective distance metric for microbial community comparison. ISME J
2011, 5:169–172.
43. Hill TC, Walsh KA, Harris JA, Moffett BF: Using ecological diversity
measures with bacterial communities. FEMS Microbiol Ecol 2003, 43:1–11.
44. Human Microbiome Project Consortium: Structure, function and diversity
of the healthy human microbiome. Nature 2012, 486:207–214.
45. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras
M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B,
Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC,
Knights D, Knight R, Gordon JI: Human gut microbiome viewed across
age and geography. Nature 2012, 486:222–227.
46. Storey JD: A direct approach to false discovery rates. J Roy Stat Soc B
2002, 64:479–498.
47. McHardy I, Goudarzi M, Tong M, Ruegger P, Schwager E, Weger J, Graeber T,
Sonnenburg J, Horvath S, Huttenhower C, McGovern DPB, Fornace AF,
Borneman J, Braun J: Integrative analysis of the microbiome and
metabolome of the human intestinal mucosal surface reveals exquisite
inter-relationships. Microbiome 2013, 1:17.
48. Murphy EC, Frick IM: Gram-positive anaerobic cocci - commensals and
opportunistic pathogens. FEMS Microbiol Rev 2013, 37:520–553.
McHardy et al. Microbiome 2013, 1:26 Page 12 of 12
http://www.microbiomejournal.com/content/1/1/2649. Bostanci N, Belibasakis GN: Porphyromonas gingivalis: an invasive and
evasive opportunistic oral pathogen. FEMS Microbiol Lett 2012, 333:1–9.
50. Kaplan CW, Lux R, Haake SK, Shi W: The Fusobacterium nucleatum outer
membrane protein RadD is an arginine-inhibitable adhesin required for
inter-species adherence and the structured architecture of multispecies
biofilm. Mol Microbiol 2009, 71:35–47.
51. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, Behre CJ, Knight
R, Fagerberg B, Ley RE, Backhed F: Human oral, gut, and plaque
microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011,
108(Suppl 1):4592–4598.
52. Lee HR, Jun HK, Kim HD, Lee SH, Choi BK: Fusobacterium nucleatum GroEL
induces risk factors of atherosclerosis in human microvascular
endothelial cells and ApoE(−/−) mice. Mol Oral Microbiol 2012, 27:109–123.
53. Roberts GL: Fusobacterial infections: an underestimated threat.
Br J Biomed Sci 2000, 57:156–162.
54. Han YW, Redline RW, Li M, Yin L, Hill GB, McCormick TS: Fusobacterium
nucleatum induces premature and term stillbirths in pregnant mice:
implication of oral bacteria in preterm birth. Infect Immun 2004,
72:2272–2279.
55. McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, Sandler RS, Keku TO:
Fusobacterium is associated with colorectal adenomas. PLoS One 2013,
8:e53653.
56. Guinane CM, Tadrous A, Fouhy F, Ryan CA, Dempsey EM, Murphy B,
Andrews E, Cotter PD, Stanton C, Ross RP: Microbial composition of
human appendices from patients following appendectomy. MBio 2013,
4:e00366–12.
57. Swidsinski A, Dorffel Y, Loening-Baucke V, Theissig F, Ruckert JC, Ismail M,
Rau WA, Gaschler D, Weizenegger M, Kuhn S, Schilling J, Dörffel WV: Acute
appendicitis is characterised by local invasion with Fusobacterium
nucleatum/necrophorum. Gut 2011, 60:34–40.
58. Warren R, Freeman D, Pleasance S, Watson P, Moore R, Cochrane K,
Allen-Vercoe E, Holt R: Co-occurrence of anaerobic bacteria in colorectal
carcinomas. Microbiome 2013, 1:16.
59. Klein DB, Hurley LB, Horberg MA, Silverberg MJ, Follansbee SE, Flamm JA,
Green GM: Increased rates of appendicitis in HIV-infected men:
1991–2005. J Acquir Immune Defic Syndr 2009, 52:139–140.
60. Nayudu SK, Balar B: Colorectal cancer screening in human
immunodeficiency virus population: Are they at average risk? World J
Gastrointest Oncol 2012, 4:259–264.
61. Bini EJ, Green B, Poles MA: Screening colonoscopy for the detection of
neoplastic lesions in asymptomatic HIV-infected subjects. Gut 2009,
58:1129–1134.
62. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ: Roseburia
intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium
from human faeces. Int J Syst Evol Microbiol 2002, 52:1615–1620.
63. Watanabe Y, Nagai F, Morotomi M: Characterization of
Phascolarctobacterium succinatutens sp. nov., an asaccharolytic,
succinate-utilizing bacterium isolated from human feces. Appl Environ
Microbiol 2012, 78:511–518.
64. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ,
Hernandez RD, Lederman MM, Huang Y, Somsouk M, Deeks SG, Hunt PW,
Lynch SV, McCune JM: Dysbiosis of the Gut Microbiota Is Associated with
HIV Disease Progression and Tryptophan Catabolism. Sci Transl Med 2013,
5:193ra191.
65. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI: The effect
of diet on the human gut microbiome: a metagenomic analysis in
humanized gnotobiotic mice. Sci Transl Med 2009, 1:6ra14.
66. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M,
Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R,
Nessel L, Li H, Bushman FD, Lewis JD: Linking long-term dietary patterns
with gut microbial enterotypes. Science 2011, 334:105–108.67. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, Harris
HM, Coakley M, Lakshminarayanan B, O'Sullivan O, Fitzgerald GF, Deane J,
O'Connor M, Harnedy N, O'Connor K, O'Mahony D, van Sinderen D, Wallace
M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross
RP, O'Toole PW: Gut microbiota composition correlates with diet and
health in the elderly. Nature 2012, 488:178–184.
doi:10.1186/2049-2618-1-26
Cite this article as: McHardy et al.: HIV Infection is associated with
compositional and functional shifts in the rectal mucosal microbiota.
Microbiome 2013 1:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
